Massive hydromorphone dose delivered subcutaneously instead of intrathecally: Guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose

Journal of Pain and Symptom Management

Volumn 28, Issue 3, 2004, Pages 273-276

  Coyne, Patrick J ^a,b   Hansen, Lea Ann ^a   Laird, Jill ^a   Buster, Patricia ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

baclofen; clonidine; emergencies; implantable devices; intraspinal therapy; intrathecal therapy; local anesthetics; opioids; overdose; Pain

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; BACLOFEN; CLONIDINE; FENTANYL; HYDROMORPHONE; HYDROXYUREA; MORPHINE; NALOXONE; OPIATE;

ADULT; ALLERGY; ARTICLE; CASE REPORT; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; FEMALE; HUMAN; PRACTICE GUIDELINE; SICKLE CELL ANEMIA;

EID: 4344632846     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2003.11.011     Document Type: Short Survey

References (4)

1. Smith T.J., Staats P.S., Deer T., et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 20:2002;4040-4049
2. Bennett G., Burchiel K., Buchser E., et al. Clinical guidelines for intraspinal infusion: report of an expert panel. J Pain Symptom Manage. 20:2000;S37-S43
3. MICROMEDEX(R) Healthcare Series Vol. 117.
4. Coffey R., Edgar T., Francisco G., et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 83:2000;735-741